Abstract
Antigenically well-matched vaccines against highly pathogenic avian influenza H5N1 viruses are urgently required. Human serum samples after immunization with MF59 or nonadjuvanted A/duck/Singapore/97 (H5N3) vaccine were tested for antibody to 1997-2004 human H5N1 viruses. Antibody responses to 3 doses of nonadjuvanted vaccine were poor and were higher after MF59-adjuvanted vaccine, with seroconversion rates to A/HongKong/156/97, A/HongKong/213/03, A/Thailand/16/04, and A/Vietnam/1203/04 of 100% (P < .0001), 100% (P < .0001), 71% (P = .0004), and 43% (P = .0128) in 14 subjects, respectively, compared with 27%, 27%, 0%, and 0% in 11 who received nonadjuvanted vaccine. These findings have implications for the rational design of pandemic vaccines against influenza H5.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adjuvants, Immunologic*
-
Adolescent
-
Adult
-
Animals
-
Antibodies, Viral / immunology
-
Cross Reactions / immunology*
-
Ducks / virology
-
Enzyme-Linked Immunosorbent Assay
-
Female
-
Hong Kong / epidemiology
-
Humans
-
Influenza Vaccines / administration & dosage
-
Influenza Vaccines / immunology*
-
Influenza Vaccines / supply & distribution
-
Influenza in Birds / epidemiology
-
Influenza in Birds / immunology*
-
Influenza in Birds / prevention & control
-
Influenza in Birds / virology*
-
Male
-
Middle Aged
-
Neutralization Tests
-
Orthomyxoviridae / classification*
-
Orthomyxoviridae / genetics
-
Orthomyxoviridae / immunology*
-
Orthomyxoviridae / pathogenicity
-
Singapore / epidemiology
-
Thailand / epidemiology
-
Vaccination
-
Vietnam / epidemiology
Substances
-
Adjuvants, Immunologic
-
Antibodies, Viral
-
Influenza Vaccines